Develops and commercializes small molecule drugs for CNS disorders. Offers NUPLAZID, the first FDA-approved treatment for Parkinson's disease psychosis. Now — the numbers.
This is an established company with proven profits.
Average growth of 22% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $767.5M would still be left in the vault — a solid cushion for hard times.
Buys outnumber sells, but taken together the trades don’t add up to a strong signal of confidence.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 17% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 36% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 22% a year on average.
There is $819.7M in the vault; even if every debt were paid off, $767.5M would remain.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, ACAD sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ACAD is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
Analysts’ average target sits above today’s price, yet the valuation grade (55/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.